poisar

Stock

4D Molecular Therapeutics, Inc. FDMT

$11.16+1.59%

Overview

FDMT market data

Price History

FDMT price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.42
Diluted earnings per share over the trailing twelve months.
Beta
2.78
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.68 – $12.34
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $505 · P/B 0.85 · P/S 5.72.

Company news

7 captured
4D Molecular's One-Shot Eye Therapy Delivers Two-Year WinBenzinga · Jul 20, 2026, 1:05 PM
8-K filing — 4D Molecular Therapeutics, Inc. (FDMT)SEC EDGAR · Jul 20, 2026, 12:30 PM
HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price TargetBenzinga · Jul 20, 2026, 10:57 AM
Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction At 2 Years, With 87% Reduction In Recently Diagnosed Wet Age-Related Macular Degeneration SubgroupBenzinga · Jul 20, 2026, 6:54 AM
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules CapitalGlobenewswire Inc · Jun 29, 2026, 12:15 PM
4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular DegenerationBenzinga · Jun 29, 2026, 12:05 PM
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · Jun 18, 2026, 5:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock